Note 9 - Segment Information and Disaggregated Revenue

9 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 9. Segment Information and Disaggregated Revenue

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The Company has divided its operations into two reportable segments as follows: Contract Manufacturing, and Other Nutraceutical Businesses. International sales, concentrated primarily in Europe, for the three months ended March 31, 2023 and 2022 were $2,188 and $2,562, respectively and for the nine months ended March 31, 2023 and 2022 were $6,576 and $7,139, respectively.

Financial information relating to the three months ended March 31, 2023 and 2022 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2023	$	10,417	$	2,180	$	12,597	$	978	$	86	$	16
	2022		12,686		2,554		15,240		1,840		82		143
Other Nutraceutical Businesses	2023		493		8		501		30		-		-
	2022		386		8		394		142		1		-
Total Company	2023		10,910		2,188		13,098		1,008		86		16
	2022		13,072		2,562		15,634		1,982		83		143

Financial information relating to the nine months ended March 31, 2023 and 2022 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2023	$	29,272	$	6,568	$	35,840	$	2,745	$	265	$	98
	2022		34,559		7,077		41,636		4,691		244		451
Other Nutraceutical Businesses	2023		1,830		8		1,838		330		2		-
	2022		1,281		62		1,343		465		3		-
Total Company	2023		31,102		6,576		37,678		3,075		267		98
	2022		35,840		7,139		42,979		5,156		247		451

	Total Assets as of
	March 31,		June 30,
	2023		2022
Contract Manufacturing	$	20,830	$	19,061
Other Nutraceutical Businesses		6,050		6,189
Total Company	$	26,880	$	25,250